XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
  AIDS
  Influenza
  MRSA
  Tuberculosis
  Shigella
  HCV
  SARS
  Ebola
  Dengue
  Malaria
  Pertussis
  Mumps
  Prion Diseases
  Small Pox
  Anthrax
  Leishmaniasis
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
 
 India
Search

Last Updated: Nov 18, 2006 - 12:32:53 PM

AIDS Channel
subscribe to AIDS newsletter

Latest Research : Infectious Diseases : AIDS

   DISCUSS   |   EMAIL   |   PRINT
HIV exploits competition among T-cells
Oct 17, 2006 - 2:08:00 AM, Reviewed by: Dr. Priya Saxena

"Once the immune system chooses a winning set of T cells, it has a natural tendency to go with those cells when it's confronted by new strains of the same disease in the future. For HIV, which mutates rapidly, this is an Achilles' heel. We found a direct correlation between the level of competition among T cells and the rate at which the virus escaped."

 
A new HIV study shows how competition among the human immune system's T cells allows the virus to escape destruction and eventually develop into full-blown AIDS. The study, which employs a computer model of simultaneous virus and immune system evolution, also suggests a new strategy for vaccinating against the virus � a strategy that the computer simulations suggest may prevent the final onset of AIDS.

"Competition among T cells exerts a small influence for most diseases, but it's fatal for HIV," said study co-author Michael Deem, Rice University's John W. Cox Professor in Biochemical and Genetic Engineering and professor of physics and astronomy.

The new computer model, created by Deem and Guanyu Wang, now an assistant professor of physics at George Washington University, is the first to accurately reproduce all three stages of HIV infection. The first is marked by an initial spike in virus production that's immediately followed by dramatic drop as the immune system recognizes the threat, mounts a defense and destroys most of the invading viruses. The second phase is a long period of clinical latency that can last up to 10 years. In this phase, a small amount of virus mutates fast enough to escape initial detection and continues to mutate over time. The third phase, AIDS, occurs when the virus has changed so much that the body's T cells are no longer effective at keeping it in check.

Deem and Wang's computer model accurately describes all three phases of HIV infection by incorporating a key component: competition among T cells. The model includes two forms of competition. The first form leads to a phenomenon known as deceptive imprinting, or original antigenic sin. Original antigenic sin is the tendency for memory immune cells produced in response to a first viral infection to suppress the creation of new immune cells in response to a second infection by a related strain. The second type of competition, immunodominance, occurs when several viral strains simultaneously infect one person. In this case, T cells compete to recognize the different strains. The winners � the T cells that the body produces in mass quantities to fight the disease � are the ones with the best overall record against the most recogniztable strains. Among the losers, however, there may be T cells that better control the other less recognizable, but still deadly, strains.

"Once the immune system chooses a winning set of T cells, it has a natural tendency to go with those cells when it's confronted by new strains of the same disease in the future," Deem said. "For HIV, which mutates rapidly, this is an Achilles' heel. We found a direct correlation between the level of competition among T cells and the rate at which the virus escaped."

Deem said one strategy to combat this effect would be to vaccinate against the strains of HIV that will inevitably evolve in the body in a manner that was designed to reduce immunodominance. One such strategy � polytopic vaccination � involves giving vaccines against different strains of the same disease simultaneously in different parts of the body. The approach capitalizes on the fact that different lymph nodes � the sites where T cells compete to be chosen as the winners against a particular disease � act as collection points for different parts of the body. Moreover, because it takes 4-5 days for T cells produced in a lymph node to begin to leave it, the possibility exists to set up simultaneous, independent competition against each of the multiple strains that will evolve by injecting each strain simultaneously so that they drain to different lymph nodes. In this case, no single T cell is chosen as a winner. Instead, a separate winner for each strain is picked in each affected lymph node before immunodominance can come into play.

"In our simulations, this strategy appears effective at all but eliminating competition among T cells," Deem said. "As a result, HIV remained in a state of permanent latency and was never able to escape the immune system's grasp to develop into AIDS."
 

- Physical Review Letters
 

The research, which is slated for publication in Physical Review Letters, is available online

 
Subscribe to AIDS Newsletter
E-mail Address:

 

Deem's research is supported by the Fundamental Laws of Biology (FunBio) Program of the Defense Advanced Research Projects Agency.

Related AIDS News

Keeping A3G in action represents a new way to attack HIV
Fighting HIV With HIV Virus Itself
HIV exploits competition among T-cells
Harmless GB Virus type C (GBV-C) protects against HIV infection
Study defines effective microbicide design for HIV/AIDS prevention
HIV depends on human p75, study shows
Simplified treatment of HIV infection shows promise
Clinical trial evaluates first-line approaches for treating HIV
T cells activated to fight HIV basis for dendritic cell therapeutic vaccine
B cells with special protein direct HIV to T cells


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us